• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.

作者信息

Giannelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O

机构信息

Istituto di Clinica Medica II, Università Degli Studi di Bari, Italy.

出版信息

J Interferon Res. 1993 Feb;13(1):57-60. doi: 10.1089/jir.1993.13.57.

DOI:10.1089/jir.1993.13.57
PMID:8454912
Abstract

The 2',5'-oligoadenylate (2-5A) synthetase is an intracellular enzyme induced by interferon (IFN). We evaluated the serum level of this enzyme in 25 patients affected by chronic hepatitis C and treated with recombinant IFN-alpha 2b. At the end of treatment, 14 patients were classified as responders and 11 as nonresponders. Before therapy initiation no significant differences in 2-5A synthetase levels among the patients were detected, while during therapy responders showed higher mean levels of 2-5A synthetase than nonresponders. An increase in the enzyme activity was observed after 1 month of therapy, and this trend was maintained in the following 2 months. The peak of 2-5A synthetase activity was found at the end of therapy. 2-5A synthetase levels were negatively correlated with serum alanine aminotransferase (ALT). This study suggests that 2-5A synthetase may be a useful marker to monitor IFN efficacy during treatment and to predict the clinical response.

摘要

相似文献

1
2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
J Interferon Res. 1993 Feb;13(1):57-60. doi: 10.1089/jir.1993.13.57.
2
Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Liver. 1993 Oct;13(5):253-8. doi: 10.1111/j.1600-0676.1993.tb00640.x.
3
Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
J Formos Med Assoc. 1997 May;96(5):314-9.
4
Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.通过持续皮下注射α-干扰素治疗慢性丙型肝炎。
J Med Virol. 1992 Jul;37(3):215-9. doi: 10.1002/jmv.1890370312.
5
2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
Gastroenterol Jpn. 1991 Oct;26(5):603-10. doi: 10.1007/BF02781676.
6
Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
Am J Hematol. 1993 May;43(1):1-4. doi: 10.1002/ajh.2830430102.
7
2',5'-Oligoadenylate synthetase activity in peripheral blood lymphocytes as a clinical marker in interferon therapy for chronic hepatitis B.外周血淋巴细胞中2',5'-寡腺苷酸合成酶活性作为慢性乙型肝炎干扰素治疗的临床标志物
J Interferon Res. 1987 Feb;7(1):111-9. doi: 10.1089/jir.1987.7.111.
8
Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.α干扰素(IFN-α)对慢性丙型肝炎患者外周血单个核细胞中2'-5'寡腺苷酸合成酶活性的影响:与IFN-α抗病毒效果的关系。
Antimicrob Agents Chemother. 1996 Feb;40(2):320-4. doi: 10.1128/AAC.40.2.320.
9
Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.慢性丙型肝炎患者血清中可溶性干扰素α/β受体水平作为干扰素抑制因子的研究
Hepatology. 1999 Nov;30(5):1325-31. doi: 10.1002/hep.510300516.
10
2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.接受α-2b干扰素维持治疗的多发性骨髓瘤患者的2',5'-寡腺苷酸合成酶水平与临床反应无关。
Br J Cancer. 1995 Dec;72(6):1525-30. doi: 10.1038/bjc.1995.541.

引用本文的文献

1
Characteristics of Human OAS1 Isoform Proteins.人 OAS1 同工型蛋白的特性。
Viruses. 2020 Jan 29;12(2):152. doi: 10.3390/v12020152.
2
A novel RNA molecular signature for activation of 2'-5' oligoadenylate synthetase-1.一种用于激活2'-5'寡腺苷酸合成酶-1的新型RNA分子特征。
Nucleic Acids Res. 2015 Jan;43(1):544-52. doi: 10.1093/nar/gku1289. Epub 2014 Dec 4.
3
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.干扰素-α-2b 加利巴韦林:关于其在慢性丙型肝炎治疗中应用的综述
Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009.
4
Alpha-Interferon for the treatment of idiopathic sudden sensorineural hearing loss.
Eur Arch Otorhinolaryngol. 1997;254(3):158-62. doi: 10.1007/BF02471282.
5
Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.α干扰素(IFN-α)对慢性丙型肝炎患者外周血单个核细胞中2'-5'寡腺苷酸合成酶活性的影响:与IFN-α抗病毒效果的关系。
Antimicrob Agents Chemother. 1996 Feb;40(2):320-4. doi: 10.1128/AAC.40.2.320.
6
Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.干扰素α-2a。其药理学特性及在病毒性肝炎治疗中的应用综述。
Drugs. 1995 Nov;50(5):873-96. doi: 10.2165/00003495-199550050-00007.
7
Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.慢性丙型肝炎治疗期间针对α干扰素(IFN-α)的中和抗体和结合抗体的生物学及临床意义
Clin Exp Immunol. 1994 Jul;97(1):4-9. doi: 10.1111/j.1365-2249.1994.tb06571.x.